ECSP003623A - Vacuna - Google Patents

Vacuna

Info

Publication number
ECSP003623A
ECSP003623A EC2000003623A ECSP003623A ECSP003623A EC SP003623 A ECSP003623 A EC SP003623A EC 2000003623 A EC2000003623 A EC 2000003623A EC SP003623 A ECSP003623 A EC SP003623A EC SP003623 A ECSP003623 A EC SP003623A
Authority
EC
Ecuador
Prior art keywords
provides
rotavirus
single variant
vaccine
designated
Prior art date
Application number
EC2000003623A
Other languages
English (en)
Inventor
Brigitte Desiree Alberte Colau
Francoise Denamur
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of ECSP003623A publication Critical patent/ECSP003623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere a nuevas formulaciones de vacuna, a procedimientos para preparalas y a su uso en terapia. En particular, la presente invención se refiere a nuevas formulaciones de vacuna de rotavirus.
EC2000003623A 1999-08-17 2000-08-15 Vacuna ECSP003623A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9919468.0A GB9919468D0 (en) 1999-08-17 1999-08-17 Vaccine

Publications (1)

Publication Number Publication Date
ECSP003623A true ECSP003623A (es) 2002-02-25

Family

ID=10859327

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003623A ECSP003623A (es) 1999-08-17 2000-08-15 Vacuna

Country Status (12)

Country Link
EP (1) EP1676586B1 (es)
CN (1) CN101302500A (es)
AT (1) ATE454165T1 (es)
CY (1) CY1109976T1 (es)
DE (1) DE60043676D1 (es)
DK (1) DK1676586T3 (es)
EC (1) ECSP003623A (es)
ES (1) ES2339043T3 (es)
GB (1) GB9919468D0 (es)
PT (1) PT1676586E (es)
SI (1) SI1676586T1 (es)
ZA (1) ZA200201266B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015004085A2 (pt) * 2012-08-27 2017-08-08 Murdoch Childrens Res Inst método para cultivar uma cepa de rotavírus (rv); método para gerar uma rv3 atenuada em células vero; rv3 adaptada à vero isolada; composição de rv morto ou vivo atenuado; método para vacinar um indivíduo humano contra infecção por rv; método para tratar um indivíduo humano com uma infecção por rv ou em risco de desenvolver uma infecção ou reinfecção por rv; uso da rv3 de vero; anticorpo isolado; e método para detectar ou monitorar a rv3 de vero
CN112724207A (zh) * 2015-05-21 2021-04-30 厦门大学 截短的轮状病毒vp4蛋白及其用途
BR112018012181A2 (pt) * 2015-12-18 2018-11-27 Merck Sharp & Dohme formulações de vacina termicamente estáveis contra o rotavírus e métodos de uso dos mesmos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341763A (en) * 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4571385A (en) * 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
ATE170081T1 (de) 1990-11-16 1998-09-15 Childrens Hosp Medical Center Humane rotativen, impfstoffe und methoden
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants

Also Published As

Publication number Publication date
SI1676586T1 (sl) 2010-04-30
DE60043676D1 (de) 2010-02-25
DK1676586T3 (da) 2010-05-10
EP1676586B1 (en) 2010-01-06
GB9919468D0 (en) 1999-10-20
ATE454165T1 (de) 2010-01-15
PT1676586E (pt) 2010-04-07
CY1109976T1 (el) 2014-09-10
ZA200201266B (en) 2003-01-29
EP1676586A1 (en) 2006-07-05
ES2339043T3 (es) 2010-05-14
CN101302500A (zh) 2008-11-12

Similar Documents

Publication Publication Date Title
AP1768A (en) Vaccine
ES2153223T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
CY1113609T1 (el) ΔΙΑΛΥΤΟΤΗΤΑ ΙFΝ-ΒΗΤΑ-1b ΣΕ ΔΙΑΛΥΜΑΤΑ ΧΛΩΡΙΟΥΧΟΥ ΝΑΤΡΙΟΥ
DE69920767D1 (de) Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
NO2013019I1 (no) Kombinasjon omfattende aliskiren, som den frie basen eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
NO20006328L (no) Attenuerte negative tradvirus med endret interferonantagonistaktivitet for anvendelse som vaksiner og medikamenter
CY1111680T1 (el) Εμβολιο συνδυασμου απενεργοποιημενου ιου πολιομυελiτιδας
CY1109404T1 (el) Μεθοδος δια την παρασκευη προϊοντων στεροειδους ορμονης. η οποια περιλαμβανει παραγοντα σταθεροποιησεως εις μη-κρυσταλλικην μορφη
CY1120408T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες
SE0004671D0 (sv) Pharmaceutical formulation
DK1047446T3 (da) Vaccinesammensætning til Herpes Simplex virus og fremgangsmåder til anvendelser deraf
DK1138333T3 (da) Medicinske præparater til oral anvendelse
NO20073914L (no) Biologisk aktive peptider
DK0939648T3 (da) Rotavirusvaccineformuleringer
CY1109976T1 (el) Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου
DK1035133T3 (da) Fusionsproteiner, der omfatter bærere, som kan inducere et dobbelt immunrespons
ES2122973T3 (es) Vacuna de recombinante de rotavirus.
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
DK1149901T3 (da) Mutanter af pestivirus og vacciner indeholdende disse
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
ES2105984B1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
UA24024C2 (uk) Вакциhа ротавірусhа іhактивоваhа для імуhізації твариh
FI893346A0 (fi) Icke-reverterande rna-virus.